Achilles Therapeutics (NASDAQ:ACHL – Get Rating) had its price target dropped by research analysts at Chardan Capital from $17.00 to $12.00 in a research report issued on Wednesday, The Fly reports.
A number of other equities analysts also recently weighed in on ACHL. Oppenheimer downgraded Achilles Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Tuesday, December 6th. Piper Sandler decreased their target price on Achilles Therapeutics from $10.00 to $8.00 and set an "overweight" rating for the company in a research report on Tuesday, December 6th.
Get
Achilles Therapeutics alerts:
Achilles Therapeutics Trading Down 4.3 %
Shares of ACHL stock opened at $1.00 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.43 and a current ratio of 10.43. The company has a market capitalization of $38.96 million, a price-to-earnings ratio of -0.55 and a beta of 0.98. Achilles Therapeutics has a 52-week low of $0.75 and a 52-week high of $3.45. The company has a 50-day simple moving average of $1.14 and a two-hundred day simple moving average of $1.75.
Hedge Funds Weigh In On Achilles Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its position in shares of Achilles Therapeutics by 130.8% during the 1st quarter. Bank of America Corp DE now owns 10,450 shares of the company's stock valued at $31,000 after buying an additional 5,922 shares during the last quarter. Balyasny Asset Management LLC bought a new position in Achilles Therapeutics during the third quarter worth about $39,000. Sei Investments Co. purchased a new position in shares of Achilles Therapeutics in the second quarter worth about $59,000. Renaissance Technologies LLC raised its position in shares of Achilles Therapeutics by 19.6% in the first quarter. Renaissance Technologies LLC now owns 30,533 shares of the company's stock valued at $90,000 after purchasing an additional 5,000 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Achilles Therapeutics during the 4th quarter valued at approximately $28,000. 69.66% of the stock is owned by institutional investors.
Achilles Therapeutics Company Profile
(Get Rating)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
Read More
- Get a free copy of the StockNews.com research report on Achilles Therapeutics (ACHL)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ's Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
阿喀琉斯治療公司(納斯達克:ACHL-GET評級)據The Fly報道,Chardan Capital的研究分析師在週三發佈的一份研究報告中將其目標價從17.00美元下調至12.00美元。
其他一些股票分析師最近也加入了ACHL的行列。奧本海默在12月6日星期二的一份研究報告中將阿喀琉斯治療公司的評級從“跑贏大盤”下調至“市場表現”。派珀·桑德勒在12月6日(週二)的一份研究報告中將他們對阿喀琉斯治療公司的目標價從10.00美元下調至8.00美元,並為該公司設定了“增持”評級。
到達
阿喀琉斯治療學警報:
阿喀琉斯治療公司股價下跌4.3%
ACHL股票週三開盤報1.00美元。該公司的負債權益比率為0.02,速動比率為10.43,流動比率為10.43。該公司市值為3,896萬美元,本益比為-0.55,貝塔係數為0.98。阿喀琉斯治療公司的股價為0.75美元,為52周低點,52周高點為3.45美元。該公司的50日簡單移動均線切入位在1.14美元,200日簡單移動均線切入位在1.75美元。
對沖基金看好阿喀琉斯治療公司
機構投資者和對沖基金最近買賣了該公司的股票。美國銀行DE在第一季度將其在阿喀琉斯治療公司的股票頭寸提高了130.8%。美國銀行DE目前持有10,450股該公司股票,價值31,000美元,此前該公司在上一季度又購買了5,922股。Balyasny Asset Management LLC在第三季度購買了阿喀琉斯治療公司的一個新頭寸,價值約3.9萬美元。SEI Investments Co.在第二季度購買了價值約5.9萬美元的阿喀琉斯治療公司的新股票頭寸。復興科技有限責任公司在第一季度將其在阿喀琉斯治療公司的股票頭寸提高了19.6%。復興科技有限責任公司在此期間又購買了5000股,現在擁有30,533股該公司的股票,價值9萬美元。最後,Virtu Financial LLC在第四季度購買了價值約2.8萬美元的阿喀琉斯治療公司的新股份。69.66%的股票由機構投資者持有。
阿喀琉斯治療公司簡介
(獲取評級)
阿喀琉斯治療公司是一家臨床階段免疫腫瘤學生物製藥公司,開發用於治療各種實體腫瘤的精密T細胞療法。該公司的主要候選產品包括用於治療晚期非小細胞肺癌的處於I/IIa階段臨床試驗的ChIron和用於治療轉移性或復發黑色素瘤的處於I/IIa階段臨床試驗的候選產品Thetis。
閱讀更多內容
- 免費獲取StockNews.com關於跟腱治療(ACHL)的研究報告
- 化石集團:2023年你應該押注於消費者可自由支配嗎?
- 北京批發俱樂部股票在強勁業績後走高
- 每月房地產收入即將變得更大
- 千禧一代投資者面臨的3個大盤股股息挑戰
- SEA即將迎來100%的漲勢,你應該買入嗎?
接受《阿喀琉斯治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對阿喀琉斯治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。